SONABLATE
High-Intensity Focussed Ultrasound (HIFU) for targeted Therapy of Prostate Carcinoma
Description

The image-guided Sonablate HIFU (High Intensity Focused Ultrasound) surgical ablation system allows to create a customized plan for each patient’s individual prostate needs. Ultrasound energy is transmitted through the rectal wall and focused at desired locations within the prostate identified by MRI and confirmed by ultrasound.

The Sonablate transducer is powered by the Sonasource ultrasound platform, which allows physicians to:

  • Aim at specific tissue using integrated ultrasound imaging and sophisticated planning tools such as the ultrasound-MRI fusion SonaFuse.
  • Ablate with pinpoint accuracy while sparing untargeted tissue. 
  • Analyze procedure results using real-time imaging and advanced, patented TCM Technology.
Components
The Probe

The Sonablate probe delivers precise and focused ablative energy into the prostate. Various planning and control functions allow an individually adapted treatment of the prostate.

The Sonasource

The Sonasource console powers the Sonablate probe. It is comprised of several integrated programmable hardware and software modules that are used to drive and control SonaCare Medical's probes.

Also included with Sonasource is Sonachill, a water degasser, cooler and circulator used to ensure temperature stabilization and acoustic coupling.

Sonablate Disposable Kit

It is comprised of a sterile probe tip pack and a water path kit. The probe tip allows sterile patient contact required for acoustic coupling between the target tissue and energy source.

SonaFuse

The HIFU fusion platform follows an open architecture approach for the validated integration of existing mpMRI fusion biopsy platforms into the Sonablate planning software.

Segmented and annotated MRI images are imported into Sonablate and merged with live ultrasound images.

Sonablate Safety Features

Features such as Tissue Change Monitoring (TCM), Total Acoustic Power (TAP), Reflexivity Index Monitor (RIM) and others enable the surgeon to respond individually to the patient's prostate and form the basis for successful, sustainable results with fewer side effects.

SELECTED PUBLICATIONS
June 2018
A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer
S. Guillaumier, M. Peters, M. Arya, N. Afzal, S. Charman, T. Dudderidge, F. Hosking-Jervis, R. G. Hindley, H. Lewi, N. McCartan, C. M. Moore, R. Nigam, C. Ogden, R. Persad, K. Shah, J. van der Meulen, J. Virdi, M. Winkler, M. Emberton, H. U. Ahmed: A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol. 2018 Oct;74(4):422-429. doi: 10.1016/j.eururo.2018.06.006. Epub 2018 Jun 28.
April 2017
Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer
A. Kanthabalan, M. Peters, M. Van Vulpen, N. McCartan, R. G. Hindley, A. Emara, C. M. Moore, M. Arya, M. Emberton and H. U. Ahmed: Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. BJU Int. 2017 Aug;120(2): 246-256. doi: 10.1111/bju.13831. Epub 2017 Apr 3.
July 2014
Improved Outcomes with Advancements in High Intensity Focused Ultrasound Devices for the Treatment of Localized Prostate Cancer
Toyoaki U, Tetsuro T, Hakushi K, Mayura N, Sunao S, Yoshihiro N and Toshiro T: mproved Outcomes with Advancements in High Intensity Focused Ultrasound Devices for the Treatment of Localized Prostate Cancer. J Urol. 2015 Jan;193(1):103-10. doi: 10.1016/j.juro.2014.07.096. Epub 2014 Jul 28.
Learn more on:
sonacaremedical.com
We take our time with you
We look forward to getting in touch with you
Thank you for your inquiry. We will answer you as soon as possible.
This site uses cookies to improve your user experience. You may find out more about in our Privacy Policy. By using this website you accept our use of cookies.
OK